Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL9390139 | 0.98 | KDM4E (0.41) | KDM4EACHEBCHEHDAC8ALDH1A1 | |
| Bromide SCHEMBL9387792 | 0.98 | KDM4E (0.41) | KDM4EACHEBCHEHDAC8ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL1162224 | 0.83 | GPR3 (0.36) | KDM4EACHE | |
| SCHEMBL3087633 | 0.78 | KDM4E (0.44) | KDM4EACHEBCHEHDAC8NPC1 | |
| SCHEMBL11004432 | 0.77 | KDM4E (0.43) | KDM4EACHEBCHEHDAC8NPC1 | |
| SCHEMBL11004427 | 0.75 | KDM4E (0.46) | KDM4EACHEBCHEHDAC8NPC1 | |
| SCHEMBL1055898 | 0.75 | SMN1; SMN2 (0.52) | KDM4EACHEBCHEHDAC8ALDH1A1 | |
| SCHEMBL721593 | 0.75 | HDAC8 (0.50) | KDM4EACHEBCHEHDAC8ALDH1A1 | |
| SCHEMBL11286540 | 0.75 | KDM4E (0.42) | KDM4EACHEBCHEHDAC8NPC1 | |
| SCHEMBL4981749 | 0.75 | KDM4E (0.42) | KDM4EACHEBCHEHDAC8NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793900-B1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING SA (CH) | 2018-08-22 | — | — | EP | claimed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | claimed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | claimed |
| EP-2793900-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | Ares Trading S.A. (CH) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092979-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | claimed |
| US-11858951-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| CN-111183142-B | Boric acid derivatives | 默克专利股份公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3672977-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-20220153761-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-11274109-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20210317145-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| EP-2265575-A2 | SULFONAMIDES | Merck Serono S.A. (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| US-20100210619-A1 | 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis | MERCK SERONO SA (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2193126-A1 | OXADIAZOLE DIARYL COMPOUNDS | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| EP-2183224-A1 | 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Merck Serono S.A. (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009019167-A1 | 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317145-A1 | Boronic Acid Derivatives | PSMB7, PSMA7, BRD7 | KDM4E 2032/4885ACHE 1566/4885BCHE 144/4885 |
| US-20100210619-A1 | 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis | S1PR1, S1PR5, S1PR3 | KDM4E 573/4885ACHE 3924/4885BCHE 3830/4885 |
| US-20220153761-A1 | Boronic Acid Derivatives | PSMB7, PSMA7, BRD7 | KDM4E 2171/4885ACHE 2145/4885BCHE 191/4885 |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | KDM4E 1138/4885ACHE 640/4885BCHE 2531/4885 |
| US-11274109-B2 | Boronic acid derivatives | PSMB7, PSMA7, BRD7 | KDM4E 2168/4885ACHE 2179/4885BCHE 197/4885 |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | PSMB7, PSMA7, PSMB1 | KDM4E 1318/4885ACHE 3297/4885BCHE 760/4885 |
| US-11858951-B2 | Boronic acid derivatives | PSMB7, PSMA7, BRD7 | KDM4E 2171/4885ACHE 2145/4885BCHE 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.